Dating back to the third century BC in China, immunotherapy has a rich history of harnessing the power of the immune response to treat diseases. Today, immunotherapy is much more sophisticated than those initial inoculations. At the clinic, it is routinely used to fight cancer in humans and animals, as well as to treat viral diseases such as Ebola. Advances in molecular biology and biochemistry – namely, developments in antibody discovery and engineering, and breakthroughs in cell and gene therapy – have turned immunotherapy into a robust clinical weapon that now includes a diverse armamentarium (e.g., monoclonal antibody drugs, antibody-drug conjugates, CAR-Ts, etc). The bottleneck threatening immunotherapy innovation Yet, current characterization and discovery tools lack the comprehensive insight offered by proteomics to herald the next generation of immunotherapeutics. The latter tools do not provide insight into the structure such as PTMs and fail to provide information on additional chains that could be present that would affect the reproducibility, resulting in costly and time-consuming troubleshooting. In contrast to these tools, protein sequencing is an honest harbinger for the future of immunotherapy as it offers direct access to the end product – the protein. The protein sequencing solution Rapid Novor’s protein sequencing toolset includes REmAb® and REpAb®. In this webinar, we will focus on the innovative and well-established antibody monoclonal sequencing technology of REmAb®, which laid the strong foundation for the development of our polyclonal sequencing technology behind REpAb®’s antibody discovery platform. With REmAb®, our clients have been able to immortalize and patent their findings, revive cell lines that otherwise would have stalled projects or discontinued products, and most importantly fully characterize their antibodies for better engineering and clinical efficacy. Of interest to human and veterinary drug development scientists, biologics and biosimilars development scientists, scientists performing pre-clinical assay development, immunotherapy researchers, oncolytic therapy development scientists, gene therapy development scientists, gene therapy, and oncolytic therapy researchers, CAR-T, and CAR-NK development scientists
What You Will Learn
A brief primer on immunotherapy and how antibodies were and continue to be integral to its development How protein sequencing complements and enhances immunotherapy advancements Examples of REmAb®’s technology’s use cases in immunotherapy and research How REmAb® was employed to elucidate the elusive almost three-decade undetermined mechanism of action of one the most prominent drugs for treating vascular disease How REmAb®s technology was utilized to develop a novel purification method for difficult-to-characterize protein complexes How REmAb® has safeguarded breakthroughs for top pharma Metrics of REmAb: restored cell lines, continued projects, and cost savings for clients What is REmAb®’s monoclonal antibody protein sequencing and how does it work
Jennifer Crha, MSc
Sr. Scientific Sales Executive at Rapid Novor
Experience in pharma, agri, food -lead into how it ties into RN With training as an analytical chemist, Jennifer has been communicating Rapid Novor’s proteomics technology for the past several years. Jenn knows with first hand experience how tricky science can be, so her goal is to find the best solution for scientists, and works collaboratively with clients to see how Rapid Novor’s technology can speed up discovery.